Linked Life Data

16132763

Source:http://linkedlifedata.com/resource/pubmed/id/16132763

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2005-8-31
pubmed:abstractText
To clarify whether serum levels of interleukin-11 (IL-11) could be a useful marker in patients with prostate cancer, serum IL-11 was determined in 73 and 23 men with prostate cancer and benign prostate hyperplasia (BPH), respectively, before treatment. There were no statistical differences of IL-11 levels between patients with prostate cancer and BPH. Patients with hormone-resistant prostate cancer had a significantly higher level of IL-11 than those with untreated cancer. Serum IL-11 levels may be a potential tumor marker for prostate cancer progression.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0301-1623
pubmed:author
pubmed:issnType
Print
pubmed:volume
37
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
69-71
pubmed:meshHeading
pubmed:year
2005
pubmed:articleTitle
Serum interleukin-11 in patients with benign prostatic hyperplasia and prostate cancer.
pubmed:affiliation
Department of Urology, Faculty of Medicine, Toyama Medical and Pharmaceutical University, Toyama, Japan. furuyayu@med.teikyo-u.ac.jp
pubmed:publicationType
Journal Article